Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Case 28% Improvement Relative Risk Case (b) 26% c19hcq.org Behera et al. HCQ for COVID-19 PrEP Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 372 patients in India Fewer cases with HCQ (not stat. sig., p=0.29) Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 Favors HCQ Favors control
Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study
Behera et al., PLoS ONE, doi:10.1371/journal.pone.0247163 (date from earlier preprint)
Behera et al., Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched.., PLoS ONE, doi:10.1371/journal.pone.0247163 (date from earlier preprint)
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective matched case-control prophylaxis study for HCQ, ivermectin, and vitamin C with 372 healthcare workers, showing lower COVID-19 incidence for all treatments, with statistical significance reached for ivermectin.
HCQ OR 0.56, p = 0.29
Ivermectin OR 0.27, p < 0.001
Vitamin C OR 0.82, p = 0.58
Although the 28% fewer cases is not statistically significant, it is consistent with the significant 30% fewer cases [22‑38%] from meta analysis of the 73 cases results to date.
risk of case, 27.9% lower, RR 0.72, p = 0.29, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), NNT 7.2, adjusted per study, odds ratio converted to relative risk, model 2 conditional logistic regression.
risk of case, 26.3% lower, RR 0.74, p = 0.25, treatment 7 of 19 (36.8%), control 179 of 353 (50.7%), NNT 7.2, odds ratio converted to relative risk, matched pair analysis.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Behera et al., 3 Nov 2020, retrospective, India, peer-reviewed, 13 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: PLOS ONE RESEARCH ARTICLE Role of ivermectin in the prevention of SARSCoV-2 infection among healthcare workers in India: A matched case-control study Priyamadhaba Behera1, Binod Kumar Patro1, Arvind Kumar Singh1, Pradnya Dilip Chandanshive1, Ravikumar S. R. ID1, Somen Kumar Pradhan1, Siva Santosh Kumar Pentapati1, Gitanjali Batmanabane ID2*, Prasanta Raghab Mohapatra3, Biswa Mohan Padhy4, Shakti Kumar Bal3, Sudipta Ranjan Singh5, Rashmi Ranjan Mohanty6 a1111111111 a1111111111 a1111111111 a1111111111 a1111111111 1 Department of Community Medicine and Family Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 2 All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 3 Department of Pulmonary Medicine and Critical Care, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 4 Department of Pharmacology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 5 Department of Forensic Medicine and Toxicology, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India, 6 Department of General Medicine, All India Institute of Medical Sciences Bhubaneswar, Bhubaneswar, India * director@aiimsbhubaneswar.edu.in OPEN ACCESS Citation: Behera P, Patro BK, Singh AK, Chandanshive PD, S. R. R, Pradhan SK, et al. (2021) Role of ivermectin in the prevention of SARS-CoV-2 infection among healthcare workers in India: A matched case-control study. PLoS ONE 16(2): e0247163. https://doi.org/10.1371/journal. pone.0247163 Editor: Muhammad Adrish, BronxCare Health System, UNITED STATES Abstract Background Ivermectin is one among several potential drugs explored for its therapeutic and preventive role in SARS-CoV-2 infection. The study was aimed to explore the association between ivermectin prophylaxis and the development of SARS-CoV-2 infection among healthcare workers. Received: December 14, 2020 Accepted: February 2, 2021 Published: February 16, 2021 Peer Review History: PLOS recognizes the benefits of transparency in the peer review process; therefore, we enable the publication of all of the content of peer review and author responses alongside final, published articles. The editorial history of this article is available here: https://doi.org/10.1371/journal.pone.0247163 Copyright: © 2021 Behera et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Data Availability Statement: The anonymized data set has been uploaded to the public repository (figshare). The dataset can be accessed at the Methods A hospital-based matched case-control study was conducted among healthcare workers of AIIMS Bhubaneswar, India, from September to October 2020. Profession, gender, age and date of diagnosis were matched for 186 case-control pairs. Cases and controls were healthcare workers who tested positive and negative, respectively, for COVID-19 by RT-PCR. Exposure was defined as the intake of ivermectin and/or hydroxychloroquine and/or vitamin-C and/or other prophylaxis for COVID-19. Data collection and entry was done in Epicollect5, and analysis was performed using STATA version 13. Conditional logistic regression models were used to describe the associated factors for SARS-CoV-2 infection. Results Ivermectin prophylaxis was taken by 76 controls and 41 cases. Two-dose ivermectin prophylaxis..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit